ÂÜÀòÂÒÂ×

Mr. Cohen occupied senior management positions at Pfizer Inc., Sulzermedica, and St. Jude Medical. He most recently founded Miromatrix Medical Inc. (fully biologic human organs) and grew that enterprise to a $90-plus million valuation over seven years by technology development, creating and commercializing two products, extensive partnering, and business development activities, regulatory and reimbursement success, and $31 million in fundraising. Immediately prior, Mr. Cohen built significant shareholder value as CEO of Travanti Pharma Inc. (iontophoretic drug delivery) through technology, product, and business development, followed by the successful sale of the company to Teikoku Pharma. Diverse activities have included successfully taking a company public on the NYSE, initiating and developing new products through to market, establishing a manufacturing facility in a foreign tax-friendly environment, a series of acquisitions, divestitures, and licensing transactions ranging from several thousand dollars to almost one billion dollars, raising capital for early-stage companies and building sales organization in the U.S. and abroad. Mr. Cohen serves or served on the Board of Directors of seven medical technology companies. He is able to leverage thirty-five years of investor, clinical, distribution, executive, technology, venture capital, and investment banking relationships.